On May 14, 2020 Agendia, Inc., a world leader in precision oncology for breast cancer, reported that they will present new data from its ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), taking place virtually May 29-May 31, 2020 (Press release, Agendia, MAY 14, 2020, View Source [SID1234558097]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data will underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for patients throughout their treatment journey. This data builds upon existing clinical research that demonstrates the efficacy of Agendia’s MammaPrint and BluePrint testing to consistently inform optimal treatment planning.

Specific data selected for presentation will include: an evaluation of the concordance between human epidermal growth factor receptor 2 (HER2) status as put forth by the 2018 ASCO (Free ASCO Whitepaper)/CAP guideline classification and BluePrint genomic testing; an examination of specific oncogenes and their correlation with risk scoring and molecular subtyping results; the ability of a chemokine gene score and MammaPrint to predict pathologic complete response (pCR) following neoadjuvant chemotherapy.

Two other poster presentations will feature additional data sets from Agendia’s ongoing multicenter, prospective, observational trial for patients with Stage I, II, and III breast cancer (FLEX). Researchers will share data from FLEX analyses evaluating triple negative breast cancers (TNBC), as well as the clinical estrogen receptor status of Basal-Type tumors based on self-reported patient ethnicities, new gene expression profiles and investigator-initiated protocols in early stage breast cancer.

"Our MammaPrint and BluePrint assays have demonstrated the ability to uniquely guide the practice of precision oncology in helping patients and their healthcare providers create the most targeted and appropriate treatment plan," says William Audeh, MD, MS, chief medical officer at Agendia. "We continue to investigate biologic drivers of breast cancer to help reduce uncertainty when choosing a treatment regimen and these latest data sets offer additional clinical insights that we believe can translate to improved patient outcomes."

Following are details of the five Agendia abstracts that have been accepted for poster presentations at the 2020 ASCO (Free ASCO Whitepaper) Annual Congress:

TNBC subtype and clinical estrogen receptor status of genomically basal breast tumors in Caucasian, African American, and Latin American patients
Authors: Kaklamani, V., et al.
Session: Breast Cancer—Local/Regional/Adjuvant
Abstract #: 556

The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer
Authors: D’Abreo, N., et al.
Session: Health Services Research and Quality Improvement
Abstract #: TPS7088

High Risk breast cancer genes at 8q22-24 and their role in over 5000 patients evaluated with the 70-gene risk of recurrence assay
Authors: Diab, S., et al.
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #: 3569

Adding precision to 2018 ASCO (Free ASCO Whitepaper)/CAP HER2 testing guidelines in breast cancer with genomic profiling
Authors: Brufsky, A., et al.
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract #: 3570

12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy
Authors: Soliman, H., et al.
Session: Breast Cancer—Local/Regional/Adjuvant and Developmental Therapeutics—Immunotherapy
Abstract #: 591

In addition, the European Organisation for Research and Treatment of Cancer (EORTC) will be presenting nearly nine year follow-up data from the landmark MINDACT study. The independent trial, originally published in the New England Journal of Medicine in 2016, confirmed the clinical utility of MammaPrint as a prognostic tool in identifying genomic Low Risk patients who do not significantly benefit from chemotherapy.

Please follow us on our Twitter, Facebook and LinkedIn pages for unique content we will be sharing throughout ASCO (Free ASCO Whitepaper).

The ASCO (Free ASCO Whitepaper) 2020 virtual program can be found in our Resources section of our website.